DXCM vs GMED Stock Comparison
Compare DXCM and GMED across AIQ Score, fundamentals, valuation, momentum, risk, analyst expectations and current market evidence.
What is the main difference between DXCM and GMED?
DXCM and GMED are close on the current AIQ evidence, so the better fit depends more on objective, risk tolerance and valuation preference than on a single headline score.
AlgovestIQ AIQ Comparison
DexCom, Inc. vs Globus Medical, Inc.
DXCM and GMED are effectively level
DXCM and GMED are effectively level on the AIQ Score; the factor table below shows where each one holds its advantage.
DexCom, Inc.
Globus Medical, Inc.
The Algovestiq AIQ Score does not currently separate DXCM and GMED as of Sep 11, 2026. Both names are scored on the same 0–100 scale across Quality, Value, Momentum and Risk Resilience, and the factor table below shows where each one holds its advantage.
Compare DexCom, Inc. and Globus Medical, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price-return comparison using available daily close history.
Total return comparison
Growth of $10,000
Based on available close-price history. Distribution reinvestment is not added unless already reflected in the source series.
Compare DXCM and GMED against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Value28 vs 55GMED +27
- Momentum42 vs 21DXCM +21
- Quality86 vs 71DXCM +15
- Risk Resilience60 vs 74GMED +14
Neither name separates cleanly on the covered dimensions.
What changed since the last close
Latest scored session 2026-09-10, compared against the prior scored session 2026-09-09.
Largest factor move: Momentum +1
No new signals fired.
No factor moved materially.
No new signals fired.
GMED's lead narrowed by 1 AIQ points in the latest snapshot.
Deeper signal detail for each name lives on its own signals page — DXCM and GMED both carry a full feed there.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
EvenNeither separates on the overall score.
Growth
DXCMDXCM on combined revenue and EPS growth.
Value
GMEDGMED on the peer-relative Value factor, by 27 points.
Momentum
DXCMDXCM on the Momentum factor, by 21 points.
Lower downside
GMEDGMED on Risk Resilience, by 14 points.
Analyst upside
GMEDGMED on implied upside to the consensus price target.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | DXCM | GMED | Note |
|---|---|---|---|
| Implied upside to target | +5.6% | +33.3% | GMED has more room |
| Target dispersion | +46.8% | +37.4% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 14 | 8 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
How each independent group of evidence reads the pair.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | Even | 54 vs 54 |
| Fundamentals | DXCMon balance | revenue growth 9.8% vs 3.9%; EPS growth 25% vs 21.7%; TTM ROE 36.2% vs 11.6%; gross margin 62.5% vs 68.5%; operating margin 22.9% vs 20.8% — DXCM takes 4 of 5 decided legs, not all of them |
| Valuation | GMED | Value 28 vs 55 |
| Technicals | DXCM | Price vs 50-day 1.1% vs -7.8%; vs 200-day 18.6% vs -13.1% |
| Risk Resilience | GMED | Risk Resilience 60 vs 74 |
| Analyst expectations | GMED | Target upside 5.6% vs 33.3% |
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is narrow at 0 points. (argues the conclusion is provisional)
- Only 1 of 6 covered evidence groups agree. (argues the conclusion is provisional)
- The leader's advantage has been narrowing. (argues the conclusion is provisional)
How the comparison changed
119 daily snapshots · May 4 – Sep 10GMED lead: Weakening — the AIQ differential moved from 7 to 0 points over 30 sessions.
- Today
- Level
- 54 vs 54
- 7 sessions ago
- DXCM +3
- 57 vs 54
- 30 sessions ago
- GMED +7
- 61 vs 68
- 90 sessions ago
- Level
- 57 vs 57
The lead changed hands 5 times in this window, most recently on Aug 28 when DXCM moved ahead of GMED.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
3 bullish / 1 bearish, conflicted
- Golden Cross Active — bullish, trend, long horizon (15.24%)
- EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
- Uptrend Structure Active — bullish, trend, long horizon
1 bullish / 4 bearish, conflicted
- Death Cross Active — bearish, trend, long horizon (6.59%)
- Keltner Channel Breakdown — bearish, volatility, short horizon
- RSI Oversold - Potential Bounce — bullish, momentum, short horizon
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Price is down while the AIQ Score moved up 1 points over the same session — price and model disagree (price -1.75%, AIQ +1 points).
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +0.86%, AIQ 0 points).
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
DXCM leads on balance| Metric | DXCM | GMED |
|---|---|---|
| Revenue growth (YoY) | 9.8% | 3.9% |
| EPS growth (YoY) | 25% | 21.7% |
| Gross margin | 62.5% | 68.5% |
| Operating margin | 22.9% | 20.8% |
| Return on equity (TTM) | 36.2% | 11.6% |
| Debt to equity | 0.53 | 0.02 |
Performance
DXCM leads 5 of 6 windows| Metric | DXCM | GMED |
|---|---|---|
| 1 week (5 sessions) | -5.8% | -8.8% |
| 1 month (20 sessions) | -6.9% | -14.1% |
| 3 months (63 sessions) | 13% | -9% |
| 6 months (126 sessions) | 27.4% | -15.6% |
| Year to date | 27.3% | -13.6% |
| 1 year (252 sessions) | 8.3% | 23.5% |
Technicals
DXCM has the stronger structure| Metric | DXCM | GMED |
|---|---|---|
| RSI (14) | 31.5 | 15.2 |
| ADX (14) | 25.7 | 22 |
| Price vs 50-day | 1.1% | -7.8% |
| Price vs 200-day | 18.6% | -13.1% |
| Volatility (1M, annualized) | 23.1% | 27.2% |
Risk
GMED is the more resilient| Metric | DXCM | GMED |
|---|---|---|
| Beta | 0.66 | 0.78 |
| Sharpe ratio | 0.29 | 0.59 |
| Sortino ratio | 0.4 | 1.34 |
| Max drawdown | -30.1% | -24% |
| Current drawdown | -8.5% | -24% |
| Annualized volatility | 41.3% | 49% |
| Value at risk (95%) | -3.7% | -3.1% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which has more analyst upside, DXCM or GMED?
Analyst price targets imply +5.6% upside for DXCM and +33.3% for GMED, so the Street currently favors GMED. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, DXCM or GMED?
GMED is the better-valued of the two on the peer-relative Value factor. GMED on the peer-relative Value factor, by 27 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, DXCM or GMED?
DXCM on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, DXCM or GMED?
DXCM on the Momentum factor, by 21 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, DXCM or GMED?
GMED is the more resilient of the two, so the other name carries the higher downside risk. GMED on Risk Resilience, by 14 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is DXCM more profitable than GMED?
The profitability evidence is mixed: gross margin 62.5% vs 68.5%; operating margin 22.9% vs 20.8%; ttm roe 36.2% vs 11.6%. DXCM leads on two measures and GMED on one measure, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.
What do the current signals say about DXCM and GMED?
DXCM: 3 bullish / 1 bearish, conflicted. GMED: 1 bullish / 4 bearish, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on DXCM is Golden Cross Active (bullish, long horizon). On GMED it is Death Cross Active (bearish, long horizon).
Compare DXCM and GMED with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.